Literature DB >> 17070376

Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.

Stephen F Wyler1, Tullio Sulser, Hans-Helge Seifert, Robin Ruszat, Thomas H Forster, Thomas C Gasser, Alexander Bachmann.   

Abstract

INTRODUCTION: Recently, some controversy has arisen as to whether pelvic lymphadenectomy is still necessary for patients with prostate cancer who are undergoing radical prostatectomy. We prospectively evaluated the results and morbidity of laparoscopic extended pelvic lymph node dissection in patients with high-risk prostate cancer defined as a serum prostate-specific antigen (PSA) level greater than 10 ng/mL or preoperative biopsy Gleason score of 7 or more. TECHNICAL CONSIDERATIONS: In 123 consecutive patients with clinically organ-confined high-risk prostate cancer, laparoscopic extended pelvic lymphadenectomy was performed before laparoscopic radical prostatectomy. The boundaries of the pelvic lymph node dissection were the bifurcation of the common iliac artery superiorly, the node of Cloquet inferiorly, the external iliac vein laterally, and the bladder wall medially. Preparation was done with bipolar forceps and scissors, with meticulous coagulation of all lymphatic tissue. The mean PSA level was 14.8 ng/mL (range 1.5 to 43.4). The mean number of lymph nodes removed was 21 (range 9 to 55). A total of 21 patients (17%) had lymph node metastases. The overall complication rate was 4%.
CONCLUSIONS: Laparoscopic extended pelvic lymph node dissection is safe and effective. The results and morbidity are equivalent to those of open surgery, with the advantage of a minimally invasive operative technique.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070376     DOI: 10.1016/j.urology.2006.04.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma.

Authors:  Liang Gao; Lu Yang; Xiao Lv; Siyuan Bu; Fan Wan; Shengqiang Qian; Qiang Wei; Ping Han; Tianyong Fan
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-27       Impact factor: 4.553

Review 2.  High-risk prostate cancer-classification and therapy.

Authors:  Albert J Chang; Karen A Autio; Mack Roach; Howard I Scher
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

3.  Multimedia article. Lateral lymph node dissection with preoperative chemoradiation for locally advanced lower rectal cancer through a laparoscopic approach.

Authors:  Tsuyoshi Konishi; Hiroya Kuroyanagi; Masatoshi Oya; Masashi Ueno; Yoshiya Fujimoto; Takashi Akiyoshi; Hidehiko Yoshimatsu; Toshiaki Watanabe; Toshiharu Yamaguchi; Tetsuichiro Muto
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

4.  Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.

Authors:  Kliton Jorgo; Csaba Polgar; Tibor Major; Gabor Stelczer; Andras Herein; Tamas Pocza; Laszlo Gesztesi; Peter Agoston
Journal:  Pathol Oncol Res       Date:  2019-03-19       Impact factor: 3.201

5.  Clinical value of extended pelvic lymph node dissection in patients subjected to radical prostatectomy.

Authors:  Jakub Dobruch; Sebastian Piotrowicz; Michał Skrzypczyk; Tomasz Gołąbek; Piotr Chłosta; Andrzej Borówka
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-02-26       Impact factor: 1.195

6.  Robot-Assisted Extended Pelvic Lymph Nodes Dissection for Prostate Cancer: Personal Surgical Technique and Outcomes.

Authors:  Francesco Porpiglia; Stefano De Luca; Riccardo Bertolo; Roberto Passera; Fabrizio Mele; Matteo Manfredi; Daniele Amparore; Ivano Morra; Cristian Fiori
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.